IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) for adjuvant atezolizumab (atezo) plus bevacizumab (bev) vs active surveillance in hepatocellular carcinoma (HCC) patients at high risk of disease recurrence after resection or ablation

被引：0

作者：

Kaseb, Ahmed ^{[1
]}

Chen, Minshan ^{[2
]}

Chow, Pierce ^{[3
,4
]}

Kudo, Masatoshi ^{[5
]}

Lee, Han Chu ^{[6
]}

Yopp, Adam ^{[7
]}

Becker, Lars ^{[8
]}

Hernandez, Sairy ^{[9
]}

Kovic, Bruno ^{[10
]}

Lian, Qinshu ^{[9
]}

Ma, Ning ^{[9
]}

Wu, Chun ^{[11
]}

Qin, Shukui ^{[12
]}

Cheng, Ann-Lii ^{[13
,14
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China

[3] Natl Canc Ctr Singapore, Singapore, Singapore

[4] Duke NUS Med Sch Singapore, Singapore, Singapore

[5] Kindai Univ, Osaka, Japan

[6] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[7] UT SouthWestern Med Ctr, Dallas, TX USA

[8] F Hoffmann La Roche, Basel, Switzerland

[9] Genentech Inc, San Francisco, CA USA

[10] Hoffmann La Roche Ltd, Mississauga, ON, Canada

[11] Roche China Holding Ltd, Shanghai, Peoples R China

[12] Nanjing Univ Chinese Med, Jinling Hosp, Nanjing, Peoples R China

[13] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

[14] Natl Taiwan Univ Hosp, Taipei, Taiwan

来源：

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

GS-011

引用

页码：S9 / S10

页数：2